Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background: Neuroblastoma remains a major therapeutic challenge for children with high-risk or relapsed/refractory disease. Anti-GD2 therapy combined with umbilical cord blood-derived natural killer (UCB-NK) cell therapy represents an emerging strategy, but responses vary substantially. Imaging and bone marrow assessments require specialized resources, creating a need for complementary tools based on routinely available data.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
